- In early May 2026, Inspire Medical Systems reported first-quarter revenue of US$204.58 million but swung to a US$11.29 million net loss, cut its full-year 2026 revenue outlook to US$825 million–US$875 million with diluted EPS of US$0.07–US$0.62, filed a US$118.82 million shelf registration for 2,600,000 ESOP-related shares, and began phasing out its classified board structure for annual director elections from 2029.
- Together with reimbursement and WISER program disruptions and subsequent analyst estimate cuts, these moves highlight both nearer-term operational pressure and an effort to strengthen long-run governance and employee ownership.
- We’ll now examine how the lowered 2026 revenue and earnings guidance may reshape Inspire Medical Systems’ investment narrative and risk profile.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Inspire Medical Systems Investment Narrative Recap
To own Inspire Medical Systems, you need to believe its implantable sleep apnea therapy can keep gaining clinical and reimbursement support despite near term setbacks. Today, the main catalyst is restoring procedure volumes as centers adapt to new coding and the WISER program, while the biggest risk is that reimbursement friction and operational missteps extend the revenue slowdown. The latest guidance cut and Q1 loss meaningfully raise execution and reimbursement risk in the near term.
The most relevant recent update is Inspire’s sharp revision of 2026 guidance to US$825 million to US$875 million of revenue and diluted EPS of US$0.07 to US$0.62. This reset contrasts with earlier expectations for growth and higher profitability, and it directly feeds into how you think about near term reimbursement issues, Inspire V rollout timing, and whether procedure volumes can recover quickly enough to support the longer term adoption story.
Yet beneath the promise of a differentiated sleep apnea solution, investors should be aware that reimbursement and coding uncertainty could...
Read the full narrative on Inspire Medical Systems (it's free!)
Inspire Medical Systems' narrative projects $1.1 billion revenue and $97.5 million earnings by 2029. This implies 8.0% yearly revenue growth but a $47.9 million earnings decrease from $145.4 million today.
Uncover how Inspire Medical Systems' forecasts yield a $79.42 fair value, a 98% upside to its current price.
Exploring Other Perspectives
Before this setback, the most optimistic analysts were assuming revenue could reach about US$1.4 billion and earnings about US$157 million by 2028, so compared with today’s guidance cut and reimbursement driven slowdown, their thesis of faster adoption and sustained margin gains looks far more optimistic and may need revisiting as the story evolves.
Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth just $51.99!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Inspire Medical Systems research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Find 50 companies with promising cash flow potential yet trading below their fair value.
- The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com